Abstract 368P
Background
Stage III non-small-cell lung cancer (NSCLC) represents a heterogeneous population ranging from apparently resectable tumors to inoperable disease. Patients diagnosed with stage III NSCLC can be treated with surgery, chemoradiotherapy, radiotherapy, and chemotherapy, depending on clinical decision by disease condition such as tumor volume, presence and number of lymph node metastasis, and patient’s background. This study aims to clarify the treatment reality in Japanese patients with stage III NSCLC.
Methods
A retrospective observational study was conducted in 11 institutions in Japan, and patients diagnosed as clinical stage III NSCLC during January 2013 to December 2014 were included. We evaluated the patient characteristics, details of treatments, and efficacy and safety outcomes per each treatment choice.
Results
In total, 790 patients were enrolled in this study, of whom 744 patients were full analysis set (FAS). Patient characteristics at diagnosis were as follows: Median age was 68 years old. Number of resectable and unresectable at diagnosis were 186 (25%) and 558 (75%), respectively. Number of stage IIIA and IIIB were 438 (59%) and 306 (41%). Number of patients per treatment modality was as follows: surgery (including both with and without perioperative treatment), 149 (20%); chemoradiotherapy, 343 (46%); chemotherapy alone, 165 (22%); and radiotherapy alone, 87 (12%). The proportion of stage IIIA was 96% in the surgical group and 39%-61% in the other groups. The median overall survival (mOS) of FAS was 25 months, and the 5-year survival rate was 28%. The mOS of surgery, chemoradiotherapy, chemotherapy, and radiotherapy were 43, 30, 17, and 14 months, and the 5-year survival rates were 44%, 33%, 14%, and 6%, respectively. The incidence of pneumonitis and radiation-pneumonitis in patients treated with chemoradiotherapy was 37% and in radiotherapy was 16%.
Conclusions
To our knowledge, this is the first study reporting the treatment reality in patients diagnosed with stage III NSCLC in Japan. Our study revealed the proportion of initial treatment in the real-world practice accompanied with the patient characteristics, prognosis, and safety focusing on radiation-related adverse events.
Clinical trial identification
UMIN000031385.
Editorial acknowledgement
Legal entity responsible for the study
AstraZeneca K.K.
Funding
AstraZeneca K.K.
Disclosure
H. Murakami: Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): Chugai; Honoraria (self), Research grant/Funding (institution): Eli Lilly; Honoraria (self), Research grant/Funding (institution): Taiho; Honoraria (self), Research grant/Funding (institution): Takeda; Honoraria (self): Ono; Honoraria (self): Bristol-Myers Squibb; Honoraria (self): MSD; Research grant/Funding (institution): AbbVie; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): IQVIA. H. Harada: Honoraria (self): AstraZeneca; Honoraria (self): Brainlab; Honoraria (self): Taiho; Honoraria (self): Nippon Chemiphar ; Honoraria (self): Merck Biopharma; Honoraria (self): Chugai; Honoraria (self): Novartis. S. Atagi: Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Eli Lilly; Honoraria (self), Research grant/Funding (institution): Chugai; Honoraria (self), Research grant/Funding (institution): Ono; Honoraria (self), Research grant/Funding (institution): Taiho; Honoraria (self), Research grant/Funding (institution): Boehringer Ingelheim; Honoraria (self), Research grant/Funding (institution): Pfizer; Honoraria (self), Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self): Hisamitsu; Honoraria (self): Kyowa Kirin; Research grant/Funding (institution): F. Hoffmann-La Roche. T. Tokito: Honoraria (self): AstraZeneca; Honoraria (self): Chugai; Honoraria (self): Boehringer Ingelheim. S. Oizumi: Honoraria (self), Research grant/Funding (institution): AstraZeneca. T. Kozuki: Honoraria (self), Research grant/Funding (institution): AstraZeneca; Honoraria (self), Research grant/Funding (institution): Chugai; Honoraria (self), Research grant/Funding (institution): Eli Lilly; Honoraria (self): Ono; Honoraria (self), Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant/Funding (institution): Taiho; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Nippon Kayaku; Honoraria (self): MSD; Honoraria (self): Novartis; Honoraria (self): Kyowa Kirin; Honoraria (self): Pfizer; Research grant/Funding (institution): Merck Biopharma. M. Seike: Honoraria (self): AstraZeneka; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Chugai; Honoraria (self), Research grant/Funding (institution): Taiho; Research grant/Funding (institution): Eli Lilly; Research grant/Funding (institution): Boehringer Ingelheim. M. Jinushi: Full/Part-time employment: AstraZeneca. H. Horinouchi: Honoraria (self), Research grant/Funding (institution): Bristol-Myers Squibb; Honoraria (self), Research grant/Funding (institution): MSD; Honoraria (self), Research grant/Funding (institution): Chugai; Honoraria (self), Research grant/Funding (institution): Taiho; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Astellas; Research grant/Funding (institution): Merck Serono; Research grant/Funding (institution): Genomic Health; Research grant/Funding (institution): Eli Lilly; Research grant/Funding (institution): Ono. All other authors have declared no conflicts of interest.
Resources from the same session
24P - The Pink Vans: Bringing cancer screening closer to home
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
25P - Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia
Presenter: Alexander Sultanbaev
Session: e-Poster Display Session
26P - Body mass index and clinical outcomes in Egyptian women with breast cancer: A multi-institutional study
Presenter: Amrou Mamdouh Abdeen Shaaban
Session: e-Poster Display Session
27P - Breast cancer primary site and laterality as predictive factors of prognosis: SEER based analysis for survival
Presenter: Eman Zin Eldin
Session: e-Poster Display Session
28P - Breast cancer care services at Nilai Medical Centre: A Malaysian experience
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
29P - Factors affecting breast self-examination (BSE) behaviour among female high school students in Denpasar City, Bali
Presenter: Cindy Trisina
Session: e-Poster Display Session
30P - Male breast cancer: A rural based peripheral cancer center experience
Presenter: SACHIN KHANDELWAL
Session: e-Poster Display Session
31P - The prognostic value of pre-treatment peripheral neutrophil-lymphocyte-ratio (NLR) and its correlation with mutant p53 expression in Indonesian triple negative breast cancer patients
Presenter: Rosita Purwanto
Session: e-Poster Display Session
32P - Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience
Presenter: Izzet Dogan
Session: e-Poster Display Session
33P - FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant chemotherapy (NACT) setting
Presenter: Krithikaa Sekar
Session: e-Poster Display Session